JLE

European Journal of Dermatology

MENU

The DESIRE study – psoriasis patients’ satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice Volume 19, issue 6, November-December 2009

Figures

See all figures

Authors
Läkarhuset Farsta Centrum, Hudmottagningen, Karlandaplan 6, 123 47 Farsta, Sweden, Department of Dermatology, Deventer Hospital, P.O. Box 5001, NL-7400 GC Deventer, The Netherlands, Amagerbrogade 18  3, 2300 Copenhagen S, Denmark, LEO Pharma Benelux, Hoge Mosten 16, NL-4822 NH Breda, The Netherlands

Daivobet ® (Dovobet ®) is a fixed combination ointment of calcipotriol and betamethasone dipropionate. The real-life clinical use of calcipotriol/betamethasone dipropionate treatment was assessed in this multi-centre, single-group, non-interventional study. Patients with psoriasis vulgaris who had a recent calcipotriol/betamethasone dipropionate prescription prior to the study start evaluated their satisfaction with the treatment after a 4-week course and after repeated courses for up to 6 months. Of the 1224 patients enrolled, 81.5% completed the 6-month study period. Approximately 75% of the patients were satisfied/very satisfied after one calcipotriol/betamethasone dipropionate treatment course and the satisfaction was high regardless of initial disease severity. Repeated calcipotriol/betamethasone dipropionate courses were prescribed for 22.9% of the patients and treatment satisfaction remained high (about 80%). The majority (60%) of the patients were willing to provide co-payments for calcipotriol/betamethasone dipropionate within their national health insurance system.